Pharmacological Targets in Metabolic Diseases

Part I Molecular level1. Molecular and cellular targets in the management of metabolic diseases and disorders: an overview2. Redox biology, metabolic disorders and therapeutic opportunities3. NADPH oxidase, obesity and metabolic syndrome: therapeutic opportunity4. NAPDH oxidase and diabetes mellitus: therapeutic strategies5. Targeting reactive carbonyls in metabolic disorders6. Antioxidant supplementation and metabolic disorders7. Modulation of the immune system as a pharmacological target in metabolic diseasesPart II Subcellular and cellular levels8. Modulation of mitochondrial physiology in the prevention and management of metabolic disorders9. Targeting autophagy in metabolic diseases10. Endoplasmic reticulum as a pharmacological target in metabolic diseasesII. Subsection: Organs as pharmacological targets in metabolic diseases and disorders11. The gut-brain axis as a pharmacological target in metabolic diseases12. Cardiomyopathy in metabolic diseases: pharmacological strategies13. The cardio-renal-metabolic connection as a pharmacological target14. Adipose tissue and metabolic diseases: a target for prevention and treatment of metabolic diseases15. Diabetic kidney disease: treatment and challenges16. Fatty liver disease: a therapeutical approach17. Pharmacologic intervention of nonalcoholic steatohepatitis and related cirrhosisPart III Subsection: Diabetes mellitus18. Pharmacological management of diabetes mellitus complicationsPart IV Subsection: Obesity19. Pharmacological targets in obesity20. Diet, obesity, and methylglyoxal: therapeutic opportunities21. Obesity-related dyslipidemia: pharmacological targets and opportunitiesPart V Subsection: Metabolic syndrome22. Metabolic syndrome: pharmacological strategies and challenges23. Pharmacological targets in metabolic syndrome-related dyslipidemia24. Therapeutic intervention in metabolic syndrome: present status and perspectivesPart VI Subsection: Inborn errors of metabolism25. Fatty acid oxidation disorders: a pharmacological approach26. Pharmacological treatment of phenylketonuria27. Pharmacological targets in inborn errors of metabolism in adult patientsPart VII Subsection: Natural molecules and metabolic diseases and disorders28. Polyphenols and obesity: molecular targets and therapeutic potential29. Plant molecules and diabetes mellitus: prevention and management30. Molecular targets in dyslipidemia: therapeutic potential of plant molecules31. Polyphenols and modulation of cholesterol metabolism32. Polyphenols and the control of immunometabolism as a pharmacological targetPart VIII Subsection: Microbiota and metabolic diseases and disorders33. Microbiota, metabolic disorders and pharmacological opportunities34. Plant extracts/molecules in obesity and the gut microbiota35. Microbiome/microbiota and diabetes mellitus: pharmacological opportunities and challenges36. Microbiome/microbiota and fatty liver disease: potential candidate for therapeutic interventionPart IX Subsection: Aging37. Aging, metabolic disorders and the mitochondria: pharmacological opportunitiesPart X Subsection: Nanotechnology and metabolic diseases and disorders38. Nanotechnology-related strategies for the prevention of metabolic syndromePart XI Subsection: Metabolic diseases and disorders and the environment39. Environmental pollution and metabolic diseases: a pharmacological challengePart XII Subsection: Diagnostic of metabolic diseases and disorders40. Diagnostic techniques in metabolic diseases and disorders